A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727).
E. Jonasch
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Pfizer
P. Lara
Consultant or Advisory Role - Novartis
N. M. Tannir
Consultant or Advisory Role - Abbott Laboratories; Pfizer
Honoraria - Abbott Laboratories; Pfizer
Research Funding - Pfizer